跳至主要内容
临床试验/NCT02865291
NCT02865291Unknown不适用

Safety and Effectiveness Evaluation of the ForConti Fecal Management System - Pilot Study

ForConti Medical0 个研究点目标入组 20 人开始时间: 2015年12月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
20
主要终点
Adverse events

研究概览

简要总结

The ForConti Fecal Incontinence Management System (FIMS) is indicated for the management of accidental bowel leakage due to bowel incontinence. The ForConti FIMS is designed for self-insertion to seal and help prevent the involuntary leakage of stool, liquids and gases from the rectum.

The purpose of the study is to demonstrate that the ForConti FIMS is safe and that it improves management of fecal incontinence and improves quality of life.

Patients will record bowel events in a daily diary over a 6 week period, which includes 2 weeks without using the device followed by 4 weeks using the device. Quality of Life questionnaire will be completed before and after use of the device. Stool leakage data collected when the device is not being used will be compared with data collected during use of the device to determine effectiveness.

详细描述

There are several devices for treating bowel incontinence. However, available devices have limited success. Sphincter bulking agents and electrical stimulation did not demonstrate effectiveness in clinical studies. Anal plugs did show some effectiveness but are associated with discomfort and pain. Hence, patients prefer not to use them.

The main reason for pain and discomfort with the current available anal plugs is the plug location within the anus below the dentate line. This part of the anus which is highly sensitive it causes discomfort and pain to the user. The advantage of the ForConti device is that it is designed to be located at a more inner section of the anal canal, above the dentate line, which is much less sensitive thus does not cause discomfort to the user.

This is a prospective, feasibility, non-randomized, single-arm, self-controlled study for preliminary safety and effectiveness. Total duration of the study for each patient will be 8 weeks, including follow-up.

The study will be conducted on up to 20 patients suffering from accidental bowel leakage due to bowel incontinence and who meet all of the inclusion criteria and none of the exclusion criteria. Following first 5 cases, interim preliminary safety analysis was conducted and a report submitted to Ministry of Health for approval to continue the study. Approval was granted.

Primary Safety: No device related serious adverse events. Secondary Safety: Minimal rate of device or procedure related adverse events (intra and post-operative complications) in the treatment or in the follow-up periods.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has signed the informed consent form and is willing to participate in the clinical study and data collection. Patient has the ability to self-manage insertion and removal of the device.
  • Patient age is between 18 and 85 years old
  • History of fecal incontinence for at least 6 months
  • A minimum of four incontinence episodes during the 2-week baseline period
  • Patient colon surveillance must be in compliance with the Ministry of Health National Program American Cancer Society colon for the Early Detection of Colorectal Cancer screening guidelines.
  • Patient comprehends study meaning & is capable of carrying out study duties.

排除标准

  • Spinal cord injury or other major neurological diagnosis
  • Known life threatening disease such as cancer, immune deficiency state
  • Significant cardiac arrhythmia
  • Pregnant or Breastfeeding
  • Inflammatory bowel disease
  • Anti-coagulants and anti-platelets treatment, except Aspirin (low dose: 75-100 mg/day)
  • Anorectal diseases: perianal abscess, active fistula, fissure, hemorrhoids grade 3 or 4, Pruritus ani or rectal bleeding
  • Chronic pelvic pain
  • Rectal surgery in past 6 months

研究组 & 干预措施

ForConti device

Experimental

Use the device up to 12 hours/day for 4 weeks

干预措施: ForConti device (Device)

结局指标

主要结局

Adverse events

时间窗: 6 weeks

4 weeks of use and 2 weeks follow-up

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Safety and Effectiveness Evaluation of the ForConti... | 临床试验